Doctor of Osteopathy Program year 2024 Reported 2019–2024 Source: CMS Open Payments, 2026 publication

Chelsea McCoy

Internal Medicine Newberry, SC Doctor of Osteopathy

NPI 1063869253 CMS profile 1402968

2033 Medical Park Drive, Newberry, SC 29108

Open in the dashboard

General payments

$6,516

379 records reported · program years 2019–2024

Research payments

$0

Paid to them · None reported · program years 2019–2024

Ownership & investment interest

$0

None reported

Through program year 2024, Chelsea McCoy of Newberry, SC is reported in the CMS Open Payments database as having received $6,516 across 379 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 91st percentile of Internal Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

6 rows
Year Kind Relative to this record's peak year Amount Records
2024 General $571 32
2023 General $1,180 75
2022 General $1,553 92
2021 General $1,487 95
2020 General $1,166 64
2019 General $559 21

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Chelsea McCoy
  • Internal Medicine median
  • Middle half of Internal Medicine
  • National median

In program year 2025, general payments to Chelsea McCoy were reported at $0. Among 52,115 Internal Medicine profiles paid that year, the median was $156 and the middle half received between $47 and $551.

Show as a table
Year Chelsea McCoy Internal Medicine median Middle half National median
2019 $559 $159 $48–$570 $163
2020 $1,166 $119 $33–$402 $114
2021 $1,487 $135 $37–$521 $132
2022 $1,553 $141 $42–$496 $149
2023 $1,180 $149 $45–$519 $160
2024 $571 $154 $47–$537 $164
2025 $0 $156 $47–$551 $169

Breakdown

Who paid General payments · program years 2019–2024
  1. AstraZeneca Pharmaceuticals LP $872 41 payments
  2. Amgen Inc. $801 42 payments
  3. Novo Nordisk Inc $592 34 payments
  4. Lilly USA, LLC $579 40 payments
  5. AbbVie, Inc. $388 38 payments
  6. Bayer HealthCare Pharmaceuticals Inc. $302 14 payments
  7. Salix Pharmaceuticals, a division of Bausch Health US, LLC $296 20 payments
  8. Merck Sharp & Dohme Corporation $283 19 payments
  9. Takeda Pharmaceuticals U.S.A., Inc. $251 16 payments
  10. Novartis Pharmaceuticals Corporation $245 13 payments
  11. Other $1,907 102 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2024
  1. Food and Beverage $6,433 378 payments
  2. Debt forgiveness $83 1 payment
Products named General payments · program years 2019–2024
  1. Ozempic $548 30 payments
  2. Repatha $530 27 payments
  3. XIFAXAN $460 31 payments
  4. FARXIGA $425 21 payments
  5. Otezla $370 20 payments
  6. RYBELSUS $323 23 payments
  7. JARDIANCE $315 21 payments
  8. Kerendia $302 14 payments
  9. TRULICITY $244 17 payments
  10. BREZTRI $242 14 payments
  11. Other $5,481 345 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 115 drugs

Part D claims

5,295

Median for Internal Medicine: 777

Drug cost

$489,528

Median for Internal Medicine: $73,373

Branded share of claims

21.7%

Median for Internal Medicine: 19.3%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Ozempic Semaglutide Brand 92 $101,837
Eliquis Apixaban Brand 85 $56,795
Jardiance Empagliflozin Brand 54 $42,929
Trulicity Dulaglutide Brand 33 $41,634
Xifaxan Rifaximin Brand 11 $35,192
Mounjaro Tirzepatide Brand 29 $30,022
Farxiga Dapagliflozin Propanediol Brand 22 $24,153
Soliqua 100-33 Insulin Glargine/Lixisenatide Brand 16 $16,280
Creon Lipase/Protease/Amylase Brand 11 $12,983
Repatha Sureclick Evolocumab Brand 11 $12,135

The 10 drugs with the highest cost, of 115 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 104,182 Part D prescribers listed as Internal Medicine; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 42 billing codes

Paid by Medicare

$80,561

Medicare's payments for the services billed

Medicare patients

559

Average age 76

Services billed

1,628

358 women, 201 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 55%
Ischemic heart disease 40%
Diabetes 38%
Chronic kidney disease 33%
Depression 32%
Atrial fibrillation 30%
Heart failure 29%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 20 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
JARDIANCE
  • Lilly USA, LLC $40
  • Boehringer Ingelheim Pharmaceuticals, Inc. $36
$76 54 —
MOUNJARO
  • Lilly USA, LLC $46
$46 29 —
XIFAXAN
  • Salix Pharmaceuticals, a division of Bausch Health US, LLC $45
$45 11 —
Veozah
  • Astellas Pharma US Inc $43
$43 — —
AIRSUPRA
  • AstraZeneca Pharmaceuticals LP $32
$32 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 20 in the dashboard with a free account

Records

379 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Internal Medicine in South Carolina

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2024

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record